Clover Health Investments (CLOV) Cash & Equivalents (2019 - 2026)

Clover Health Investments has reported Cash & Equivalents for 8 years, with the latest figure at $173.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 11.47% year-over-year to $173.3 million; the trailing twelve-month figure through Mar 2026 stood at $173.3 million (up 11.47% YoY), and the FY2025 full-year result was $78.3 million, down 59.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $173.3 million, up from $78.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $382.9 million in Q3 2022, with the low at $78.3 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $219.9 million across 5 years, with a median of $194.5 million in 2024.
• The largest YoY upside for Cash & Equivalents was 664.91% in 2022 against a maximum downside of 65.4% in 2022.
• Clover Health Investments' Cash & Equivalents stood at $103.8 million in 2022, then grew by 18.38% to $122.9 million in 2023, then soared by 58.34% to $194.5 million in 2024, then slumped by 59.75% to $78.3 million in 2025, then jumped by 121.28% to $173.3 million in 2026.
• The last three Cash & Equivalents figures came in at $173.3 million (Q1 2026), $78.3 million (Q4 2025), and $190.1 million (Q3 2025), per Business Quant data.